BioLineRx is trading 8.75% up now at $3.00, as investors may also be positioning ahead of the estimated August 13, 2026 Q2 earnings release.
- The stock compares with an August 11 close of $2.77.
- No new company-specific announcement clearly explains the August 12, 2026 move.
- The Nasdaq Composite is up 0.62%; the earnings preview expects a $0.02-per-share loss and $8.45 million in revenue.